ImmunoPrecise Operating Cycle from 2010 to 2026
| HYFT Stock | 1.38 0.01 0.72% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 664.56761112 | Current Value 631.34 | Quarterly Volatility 529.08007836 |
Check ImmunoPrecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunoPrecise Antibodies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.1 M, Total Revenue of 29.4 M or Gross Profit of 13.9 M, as well as many indicators such as Price To Sales Ratio of 1.7 K, Dividend Yield of 0.0863 or Days Sales Outstanding of 3.3 K. ImmunoPrecise financial statements analysis is a perfect complement when working with ImmunoPrecise Antibodies Valuation or Volatility modules.
ImmunoPrecise | Operating Cycle | Build AI portfolio with ImmunoPrecise Stock |
The evolution of Operating Cycle for ImmunoPrecise Antibodies provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how ImmunoPrecise Antibodies compares to historical norms and industry peers.
Latest ImmunoPrecise Antibodies' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of ImmunoPrecise Antibodies over the last few years. It is ImmunoPrecise Antibodies' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImmunoPrecise Antibodies' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
ImmunoPrecise Operating Cycle Regression Statistics
| Arithmetic Mean | 577.02 | |
| Geometric Mean | 332.69 | |
| Coefficient Of Variation | 91.69 | |
| Mean Deviation | 481.50 | |
| Median | 170.52 | |
| Standard Deviation | 529.08 | |
| Sample Variance | 279,926 | |
| Range | 1.2K | |
| R-Value | (0.67) | |
| Mean Square Error | 162,927 | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (70.62) | |
| Total Sum of Squares | 4.5M |
ImmunoPrecise Operating Cycle History
About ImmunoPrecise Antibodies Financial Statements
ImmunoPrecise Antibodies shareholders use historical fundamental indicators, such as Operating Cycle, to determine how well the company is positioned to perform in the future. Although ImmunoPrecise Antibodies investors may analyze each financial statement separately, they are all interrelated. The changes in ImmunoPrecise Antibodies' assets and liabilities, for example, are also reflected in the revenues and expenses on on ImmunoPrecise Antibodies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 664.57 | 631.34 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ImmunoPrecise Stock Analysis
When running ImmunoPrecise Antibodies' price analysis, check to measure ImmunoPrecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunoPrecise Antibodies is operating at the current time. Most of ImmunoPrecise Antibodies' value examination focuses on studying past and present price action to predict the probability of ImmunoPrecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunoPrecise Antibodies' price. Additionally, you may evaluate how the addition of ImmunoPrecise Antibodies to your portfolios can decrease your overall portfolio volatility.